Abstract Details

Title The Millon Behavioral Medicine Diagnostic (MBMD): A psychological characterization of individuals with Parkinson’s disease (PD) prior to deep brain stimulation (DBS)

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 062

Objective Describe a novel application of the Millon Behavioral Medicine Diagnostic (MBMD) to characterize psychiatric and psychosocial vulnerabilities in individuals undergoing deep brain stimulation (DBS) for Parkinson’s disease (PD).

Background A challenge in DBS treatment is to provide a quantitative, baseline measure of psychosocial patient characteristics that informs approaches to care. The MBMD is a multidimensional psychosocial and behavioral assessment that is widely administered pre-surgically and can identify factors that may influence a patient’s adjustment to treatment outcomes.

Design/Methods The MBMD was administered preoperatively to a sample (N = 34, 20 Males, M age = 64, 62% Caucasian) undergoing DBS for treatment of PD. The MBMD is a self-report inventory that includes 29 content scales grouped and evaluated across three response patterns, six negative health habits, and five domains. The five core domains include: psychiatric indications, coping styles, stress moderators, treatment prognostics, and management guides.

Results 24% of patients scored above threshold on the Psychiatric Referral scale, with elevations observed in two psychiatric indications content scales: Anxiety-Tension (M=60; SD=29) and Depression (M=59; SD=30). 60% of patients showed elevations on the Adjustment Difficulties scale, reflecting the most prevalent coping styles: Cooperative (M=61, SD=26) and Introversive (M =48, SD=28).

Conclusions Clinically significant psychiatric symptoms were identified in 1:4 individuals seeking DBS for treatment-refractory PD, indicative of a critical variable in DBS outcome research, as well as a need for psychiatric evaluation adjunctive to intervention with DBS. Prevalent coping styles indicate a higher likelihood of patient withdrawal and lack of initiative, despite treatment compliance, which may influence a sense of agency in medical care. Future work with these data will examine relevant MBMD factors as targets for behavioral health services, as well as predictors of patient satisfaction with DBS, quality of life, and treatment outcomes after 6 months of DBS for PD.

Authors/Disclosures
Shannon O'Neill, PhD (Mount Sinai West) PRESENTER	Shannon O'Neill has nothing to disclose.
	No disclosure on file
Joohi Jimenez Shahed, MD, F�鶹��ýӳ�� (Icahn School of Medicine at Mount Sinai)	Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with �鶹��ýӳ��. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.

�鶹��ýӳ��

�鶹��ýӳ��